Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04ZNL
|
|||
| Former ID |
DIB007391
|
|||
| Drug Name |
RG-7234
|
|||
| Synonyms |
R-7234; RO-5027838; 11-beta HSD 2 (type 2 diabetes), Roche; 11-beta hydroxysteroid dehydrogenase inhibitor 2 (type 2 diabetes), Roche
Click to Show/Hide
|
|||
| Indication | Type-2 diabetes [ICD-11: 5A11; ICD-9: 250] | Phase 2 | [1] | |
| Company |
F Hoffmann-La Roche Ltd
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Steroid hormone biosynthesis | |||
| Aldosterone-regulated sodium reabsorption | ||||
| NetPath Pathway | EGFR1 Signaling Pathway | |||
| Pathwhiz Pathway | Steroidogenesis | |||
| Reactome | Glucocorticoid biosynthesis | |||
| WikiPathways | Prostaglandin Synthesis and Regulation | |||
| Glucocorticoid & Mineralcorticoid Metabolism | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00823680) A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin. U.S. National Institutes of Health. | |||
| REF 2 | New Therapeutic Strategies for Type 2 Diabetes: Small Molecule Approaches. 2012. Chapter 5. Page(131). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.